Akebia Therapeutics, Inc. (AKBA)

Over the past six months, Akebia Therapeutics' stock price has declined by 48.5% due to several significant events. In October 2025, the company decided not to pursue the VALOR trial for Vafseo's label expansion, leading to a 31% stock price drop. In November 2025, Akebia reported its Third Quarter 2025 financial results, with Vafseo net product revenues reaching $14.3 million and total net product revenues at $56.8 million. Akebia participated in the Piper Sandler 37th Annual Healthcare Conference in December 2025. In February 2026, the company released its Fourth Quarter and Full Year 2025 financial results, reporting Q4 2025 net product revenues of $54.3 million and full-year 2025 net product revenues of $227.3 million, a 49% increase over 2024, and granted inducement stock options to newly hired employees. Akebia presented at the Leerink Partners 2026 Global Healthcare Conference in March 2026 and granted inducement stock options to newly hired employees. In April 2026, Akebia announced investor meetings at the Raymond James 2026 Biotech Innovation Symposium, held a Virtual R&D Day, reported inducement grants, and appointed Philip Vickers, Ph.D., to its Board of Directors.

Specific, recurring seasonal patterns for the demand of Akebia Therapeutics' products and services were not explicitly detailed in the provided search results, although Vafseo's demand experienced a strong start in early 2025 but flattened in the second half of the year. Seeking Alpha displays mean and median monthly returns for AKBA to identify seasonal patterns, but the actual patterns or their impact on product demand were not provided.

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for kidney disease, operating within the pharmaceutical preparation manufacturing industry. The company addresses chronic kidney disease (CKD) and related rare kidney disorders, with commercial products like Vafseo (vadadustat) for anemia due to CKD in adults on dialysis and Auryxia (ferric citrate) for controlling serum phosphorus levels in dialysis-dependent CKD patients and treating iron deficiency anemia in non-dialysis-dependent CKD patients. Akebia's pipeline includes praliciguat, AKB-097, AKB-9090, and other HIF-PH inhibitors in preclinical development, targeting conditions such as FSGS, complement-mediated kidney diseases, and acute kidney injury.

Akebia Therapeutics is headquartered in Cambridge, Massachusetts. The company has a global reach through its development organization and partners, with Vafseo approved for use in 37 countries.

Akebia Therapeutics' brand reputation has been negatively impacted by the decision to abandon the VALOR trial for Vafseo in non-dialysis CKD patients. This decision, due to a lack of FDA alignment on trial design, led to a stock price drop and investigations by law firms into potential securities law violations, including class action lawsuits, affecting the company's reputation among investors and the medical community.

Institutional investors hold a significant portion of Akebia Therapeutics' outstanding shares. As of December 2025, 165 institutional investors collectively held 43.1% of the shares, and by April 2026, 171 institutional owners held a total of 118,577,668 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, State Street Corp, Geode Capital Management, LLC, Goldman Sachs Group Inc, Citadel Advisors LLC, Renaissance Technologies LLC, Qube Research & Technologies Ltd, Citigroup Inc, and Northern Trust Corp. The CEO, John Butler, held 0.6% as of January 2026, and insiders have bought more company stock than they have sold in the past three months.